Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics to advance AI capabilities in its heart device with new gov't funding

The firm is set to partner Ryerson University on the project
VentriPoint Diagnostics to advance AI capabilities in its heart device with new gov't funding
Ventripoint is partnering with Ryerson University

Medical imaging firm VentriPoint Diagnostics Ltd (CVE:VPT) revealed its technology has been further boosted by a government grant.

The firm is set to partner Ryerson University on a project to further advance the Al (artificial intelligence) capabilities already imbedded in the heart monitoring VMS+ products after the company revealed it is taking part in a Natural Sciences and Engineering Research Council (NSERC) Engage grant.

"This is very exciting for Ventripoint and the healthcare community at large because it allows us to bring new technology to market that will ultimately improve clinical outcomes and reduce overall cost of care," said Desmond Hirson, president of Ventripoint.

The progress is in keeping with Ventripoint's  mission of being a leader in providing medical products that use AI to enhance the productivity, accuracy and consistency of cardiac measurements, it said.

"The benefits of this technology can also be extended to other modalities and imaging technologies, such as MRI and CT, to further expand the use of AI in the field of Medical Imaging."

The firm says its VMS+ device is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.

VentriPoint shares added 1.64% to C$0.31.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use